Investigation of Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. (ODT) Accused of Misrepresenting Potential of New Cancer Drug

During the relevant period, Odonate Therapeutics, Inc. touted the extent of its clinical trials of tesetaxel and the efficacy of the drug.  Unbeknownst to shareholders, Odonate Therapeutics failed to disclose the serious safety and tolerance issues surrounding tesetaxel, which has compromised the drug’s potential commercial viability as a cancer treatment. Before market hours on August 24, 2020, Odonate released its CONTESSA trial results, shocking investors with the announcement that tesetaxel substantially increased neutropenia (low white blood cell counts), neuropathy, and other adverse events. The trial results demonstrated a discontinuation rate of just 11.9% in the control group versus 23.1% in the tesetaxel treatment group. On this news, Odonate stock price fell 43.35% to close at $18.33 per share on August 24, 2020.

If you purchased Odonate Therapeutics, Inc. (ODT) securities between December 7, 2017 and August 21, 2020, you have until November 16, 2020, to ask the court to appoint you lead plaintiff for the class.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

Ticker + Amount
This field is for validation purposes and should be left unchanged.